Shenzhen, China, March 29, 2023 – MGI signed a strategic agreement with Guangdong Hybribio Biotech Co., Ltd. (“Hybribio”) to establish a partnership aimed at expanding the international market for gene sequencing technology. Leveraging MGI’s DNBSEQ sequencing platform, Hybribio will develop precision medicine applications.
Hybribio’s Commitment to Precision Medicine
“Hybribio has engaged in molecular detection for over 20 years, focusing on the development and needs of the medical industry. We continually create efficient, intelligent, and innovative solutions to make precision medicine services more accessible. We look forward to collaborating with MGI to advance the clinical application of high-throughput sequencing in maternal and child health, birth defects, infectious diseases, and tumors, improving human health with advanced technology and products,” said Guan Zhisheng, Director & Executive Deputy General Manager of Hybribio.
MGI’s Vision for Industry Innovation
“MGI has always prioritised innovation and R&D of core life science tools to facilitate industry development and improve human health. Using our proprietary DNBSEQ technology, we have developed an extensive product portfolio covering low, medium, high and ultra-high throughput options. We are excited to join Hybribio to achieve win-win cooperation and make profound breakthroughs in clinical applications of high-throughput sequencing in precision medicine,” said Jiang Hui, COO of MGI.
High-Throughput Sequencing in Precision Medicine
High-throughput sequencing is central to precision medicine, playing a crucial role in detecting pathogenic microorganisms, early cancer screening, genetic disease detection, infectious disease monitoring, and the discovery of new viruses. MGI is one of only two companies worldwide capable of independently developing and mass-producing clinical gene sequencers. Its products provide industry-leading data quality and competitive costs across diverse application scenarios.
Strategic Collaboration Outlook
Hybribio, a leading provider of nucleic acid molecular diagnostics and private medical laboratory services, will collaborate with MGI to deepen the application of high-throughput sequencing platforms in genomics and precision medicine. This partnership aims to empower maternal and child health, birth defect detection, infectious disease management, and tumour research, driving innovation in clinical genomics.
